Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project
- PMID: 8628612
Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project
Abstract
Objective: To describe the progression of human immunodeficiency virus (HIV) disease through clinical stages from birth to death among a large number of perinatally infected children.
Methods: The Pediatric Spectrum of Disease (PSD) project, coordinated by the Centers for Disease Control and Prevention (CDC), has conducted active surveillance for HIV disease since 1988 in seven geographic regions. PSD data are collected from medical and social service records every 6 months through practitioners at each participating hospital clinic. We analyzed data from perinatally HIV-infected children born between 1982 and 1993. The natural history of HIV disease was divided into five progressive stages using the clinical categories in the CDC 1994 pediatric HIV classification system: stage N, no signs or symptoms; stage A, mild signs or symptoms; stage B, moderate signs or symptoms; stage C, severe signs or symptoms; and stage D, death. A five-stage Markov model was fitted to the PSD data. To compare the estimates from the PSD project with the published estimates, we also fitted an alternative Markov model using acquired immunodeficiency syndrome (AIDS; 1987 case definition) in place of stage C and also calculated standard Kaplan-Meier estimates.
Results: A total of 2148 perinatally HIV-infected children were included in the analysis. The estimated mean times spent in each stage were: N, 10 months; A, 4 months; B, 65 months; and C, 34 months. We estimated that a child born with HIV infection has a 50% (95% confidence interval [CI], 40%-60%) chance of severe signs or symptoms developing by 5 years of age and a 75% (95% CI, 68%-82%) chance of surviving to 5 years of age. For a child in stage B, there is a 60% (95% CI, 49%-71%) chance of severe signs or symptoms developing within the next 5 years and a 65% (95% CI, 56%-73%) chance of surviving 5 more years. The estimated mean time from birth to stage C was 6.6 (95% CI, 5.7-7.5) years, and the estimated mean survival time from birth was 9.4 (95% CI, 8.1-10.7) years. From the alternative Markov model, the estimated mean time from birth to AIDS was 4.8 (95% CI, 4.5-5.2) years.
Conclusion: Markov modeling using the revised pediatric classification system allowed us to describe the natural history of HIV disease in children before diagnosis of AIDS. On average, children progress to moderate symptoms in the second year of life and then remain moderately symptomatic for more than half of their expected lives, underscoring their need for clinical care before the onset of AIDS. The results from the Markov model are useful in family counseling, health care planning, and clinical trial designs.
Similar articles
-
Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.Int J Epidemiol. 2000 Jun;29(3):565-72. Int J Epidemiol. 2000. PMID: 10869332
-
Outcomes of human immunodeficiency virus-infected and -exposed children undergoing surgery--a prospective study.J Pediatr Surg. 2009 Apr;44(4):681-7. doi: 10.1016/j.jpedsurg.2008.08.036. J Pediatr Surg. 2009. PMID: 19361626
-
Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study.Pediatrics. 1994 Dec;94(6 Pt 1):815-9. Pediatrics. 1994. PMID: 7970995
-
Pediatric AIDS and perinatal HIV infection in Zaire: epidemiologic and pathologic findings.Prog AIDS Pathol. 1992;3(1):1-33. Prog AIDS Pathol. 1992. PMID: 1606299 Review.
-
[Socioeconomic aspects of human immunodeficiency virus (HIV) infection in developing countries].Bull Acad Natl Med. 1990 Nov;174(8):1209-19; discussion 1219-21. Bull Acad Natl Med. 1990. PMID: 2094555 Review. French.
Cited by
-
Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.Paediatr Drugs. 2000 Sep-Oct;2(5):373-407. doi: 10.2165/00128072-200002050-00005. Paediatr Drugs. 2000. PMID: 11022799 Review.
-
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.Expert Rev Anti Infect Ther. 2014 Mar;12(3):307-18. doi: 10.1586/14787210.2014.888311. Epub 2014 Feb 9. Expert Rev Anti Infect Ther. 2014. PMID: 24506199 Free PMC article. Review.
-
Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.AIDS. 2009 Apr 27;23(7):789-98. doi: 10.1097/QAD.0b013e328329c784. AIDS. 2009. PMID: 19293686 Free PMC article.
-
Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques.J Virol. 2018 Aug 29;92(18):e00562-18. doi: 10.1128/JVI.00562-18. Print 2018 Sep 15. J Virol. 2018. PMID: 29997216 Free PMC article.
-
Routine prenatal screening for HIV in a low-prevalence setting.CMAJ. 1998 Oct 20;159(8):942-7. CMAJ. 1998. PMID: 9834719 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical